PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Aqueous berry extract prevented alterations in plasma enzymes (ASAT, ALAT, ALP, LDH) and maintained antioxidant status in rats [PMID:28442109].
Aqueous leaves extract showed ameliorative effects on biochemical and histopathological parameters in experimental Swiss Albino rats [PMID:32700840].
Hydroethanolic extract (100 mg/kg BW) reduced paw oedema and MDA content in mice [PMID:30112384].
Aqueous leaf and berry extracts (300 mg/kg/day) significantly ameliorated hematological disturbances in rats [PMID:42307848].
Essential oil provided dose-dependent protection of the gastric mucosa in mice, with 81.92% protection at 200 mg/kg [PMID:42195871].
Evidence summary
PubMed sources
- 1.PMID: 21707254 (2011) — Chemical compounds from Phoenician juniper berries (Juniperus phoenicea). · Natural product research
- 2.PMID: 11558640 (2001) — Final report on the safety assessment of Juniperus communis Extract, Juniperus oxycedrus Extract, Juniperus oxycedrus Tar, Juniperus phoenicea extract, and Juniperus virginiana Extract. · International journal of toxicology
- 3.PMID: 39345860 (2024) — Phytochemical profile, physicochemical, antioxidant and antimicrobial properties of Juniperus phoenicea and Tetraclinis articulate: in vitro and in silico approaches. · Frontiers in chemistry
- 4.PMID: 35915116 (2022) — Clay and climatic variability explain the global potential distribution of Juniperus phoenicea toward restoration planning. · Scientific reports
- 5.PMID: 32700840